PARP Inhibitors Market To Witness High Growth Due To Increasing...

PARP Inhibitors Market To Witness High Growth Due To Increasing Adoption In Cancer Treatment

Posted 2023-12-15 13:50:42

PARP inhibitors are a type of targeted therapy used to treat certain cancers, including ovarian cancer, breast cancer and prostate cancer. They work by blocking an enzyme called poly (ADP-ribose) polymerase (PARP), which helps repair DNA damage in cells. When PARP is blocked, DNA damage isn't repaired properly and cancer cells cannot survive and eventually die. PARP inhibitors are primarily used as a maintenance therapy after the completion of first-line treatment for ovarian cancer or for those with a known mutation in BRCA1 or BRCA2 genes.

The global PARP inhibitor market is estimated to be valued at US$ 6.13 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
One of the major drivers fueling the growth of PARP inhibitors market is increasing adoption of these drugs for cancer treatment. PARP inhibitors are increasingly being used as a therapy for ovarian cancers, breast cancers and prostate cancers with specific mutations. According to Cancer Research UK, around 3,270 women are diagnosed with ovarian cancer each year in the UK alone. Additionally, increasing research and development activities by pharmaceutical companies to develop new PARP inhibitor drugs is also expected to boost market growth over the forecast period. For instance, in March 2022, Gehirn Therapeutics launched phase 1 clinical trial of its orally bioavailable PARP inhibitor Geh-101 for glioblastoma and other solid tumors.

SWOT Analysis

Strength: PARP inhibitors have demonstrated efficacy in treatment of certain cancers like breast and ovarian cancers. PARP inhibitors can effectively target cancer cells with defective homologous recombination repair. PARP inhibitors are being evaluated in combination with other anti-cancer drugs to expand treatment options.
Weakness: PARP inhibitors have significant drug resistance issues over time limiting their long term effectiveness. Adverse effects of PARP inhibitors like fatigue and myelosuppression reduce tolerance and compliance.
Opportunity: PARP inhibitors are being evaluated for use in newer cancer types like prostate, pancreatic and other gastrointestinal cancers expanding the market potential. Combination treatments of PARP inhibitors with immunotherapy are being researched to improve treatment outcomes.
Threats: Intense competition from other novel anti-cancer therapies may reduce the market share of PARP inhibitors. Patent expiries of major PARP inhibitor brands will increase generic competition.

Key Takeaways

The Global PARP Inhibitor Market is expected to witness high growth over the forecast period driven by increasing incidence of cancer globally. PARP inhibitors have become a mainstay in the treatment of certain cancers like breast and ovarian cancers. The approval and adoption of newer PARP inhibitors and line extensions to newer cancer indications will boost the market revenues.

Regional analysis

North America dominated the global PARP inhibitor market in 2023 and is expected to retain top position over the forecast period. Presence of major players, higher healthcare spending, faster adoption of novel therapies contribute to North American market growth. Europe is the second largest PARP inhibitor market supported by growing research on combination treatments and availability of reimbursement. Asia Pacific region offers high growth potential for PARP inhibitors market owing to rising incidence of cancer, improving access to advanced treatments and expansion of key market players in the region.

Key players

Key players operating in the PARP Inhibitor Market are AstraZeneca, GlaxoSmithKline plc, Pfizer Inc., Clovis Oncology, Inc., Tesaro (acquired by GlaxoSmithKline). The market is witnessing ongoing mergers and acquisitions as large players look to strengthen their portfolio. For instance, GlaxoSmithKline acquired Tesaro in 2018 to gain access to the latter's late stage PARP product pipeline. Companies are investing in research of combination therapies and extending indications of existing PARP inhibitor brands to counter competition.